


Supplementary materials


# Amorphous form of carvedilol phosphate - The case of divergent properties

Szymon Sip <sup>1</sup>, Natalia Rosiak <sup>1</sup>, Andrzej Miklaszewski <sup>2</sup>, Patrycja Talarska <sup>3</sup>, Ewa Dudziec <sup>4</sup> and Judyta Cielecka-Piontek <sup>1,\*</sup>


- <sup>1</sup> Department of Pharmacognosy, Poznan University of Medical Sciences, 4 Swieczkiego Street, 60-781 Poznan, Poland; szymonsip@ump.edu.pl (S.S.), nrosiak@ump.edu.pl (N.R.), jpiontek@ump.edu.pl (J.C.P.)  
<sup>2</sup> Institute of Materials Science and Engineering, Poznan University of Technology, Jana Pawła II 24, 61-138 Poznan, Poland, andrzej.miklaszewski@put.poznan.pl (A.M.)  
<sup>3</sup> Department of Immunobiology, Poznan University of Medical Sciences, ul. Rokietnicka 8, 60-806 Poznań, Poland; patrycjatalarska@ump.edu.pl (P.T.)  
<sup>4</sup> Department of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, ul. 28 Czerwca 1956 r. 135/147, 61-545 Poznań, Poland; ewa.dudziec@ump.edu.pl (E.D.)  
 \* Correspondence: jpiontek@ump.edu.pl




**Figure S1.** FT-IR spectrum of crystalline CVD - HPBCD physical mixture.




**Figure S2.** FT-IR spectrum of crystalline CVD – Soluplus® physical mixture.




**Figure S3.** FT-IR spectrum of crystalline CVD – Pluronic® F127 physical mixture.




**Figure S4.** FT-IR spectrum of amorphous CVD - HPBCD physical mixture.




**Figure S5** FT-IR spectrum of amorphous CVD – Soluplus® physical mixture.




**Figure S6.** FT-IR spectrum of amorphous CVD – Pluronic® F127 physical mixture.



**Figure S7.** Amorphous CVD diffractogram – HPBCD physical mixture.



**Figure S8.** Amorphous CVD diffractogram – Soluplus® physical mixture.



**Figure S9.** Amorphous CVD diffractogram – Pluronic® F127 physical mixture.